NOTE

🌱 created from: treatment of chronic myelogenous leukemia (CML)

ascend-cml

ASC4FIRST: Asciminib (80 mg once daily) vs. Investigator-selected TKI, Major molecular response at week 48: 67.7% vs. 49.0% (difference, 18.9 percentage points; 95% CI, 9.6 to 28.2; adjusted two-sided P<0.001); 38.0% grade 3 or higher adverse events with asciminib vs. 44.4% with imatinib and 54.9% with second-generation TKIs.

Major molecular response 比較快

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | New England Journal of Medicine